Salisbury Foundation Trust

FOI_5957

Internal Reference Number: FOI_5957

Date Request Received: 15/12/2020 13:14:52

Date Request Replied To: 28/01/2021 11:51:30

This response was sent via: By Email

Request Summary: incidence and treatment of Myelofibrosis and Oesophageal cancer

Request Category: Media






 
Question Number 1:
Does your trust treat the following conditions? If not, which other trust do you refer these patients to?
• Advanced oesophageal cancer
• Myelofibrosis
 
Answer To Question 1:
Yes
 
Question Number 2:
Please provide the total number of patients treated in the last 6 months for:
• Myelofibrosis
• Myelofibrosis – patients over the age 65
• Oesophageal cancer (any type)
• Oesophageal adenocarcinoma
• Oesophageal squamous cell carcinoma
• Unresectable Oesophageal squamous cell carcinoma
 
Answer To Question 2:
Please see the Excel spreadsheet attached containing our response to Question 2.

Please note: The patients treated for Oesophageal adenocarcinoma and Oesophageal squamous cell carcinoma are also counted in the number of patients treated for Oesophageal cancer (any type).
We have not treated any patients for Unresectable Oesophageal squamous cell carcinoma in the past 6 months.9319 - FOI_5957 - Myelofibrosis and Oesophageal cancer.xlsx
 
Question Number 3:
For the oesophageal squamous cell carcinoma patients only, how many patients were treated in the past 6 months with:
• Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
• Any other systemic anti-cancer therapy
• Palliative care only
 
Answer To Question 3:
Please see attached refusal notice explaining why the Trust will not be answering this question.
 
Question Number 4:
For myelofibrosis patients only, how many patients (of any age) were treated in the past 6 months with;
• Ruxolitinib
• Hydroxyurea
• Watch and wait approach
 
Answer To Question 4:
Please see attached refusal notice explaining why the Trust will not be answering this question.
 
Question Number 5:
Does your trust participate in any clinical trials for oesophageal cancer? If so, can you please provide the name of each trial along with the number of patients taking part?
 
Answer To Question 5:
Please see attached refusal notice explaining why the Trust will not be answering this question.
 
Question Number 6:
Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part?
 
Answer To Question 6:
Please see attached refusal notice explaining why the Trust will not be answering this question.
Please see attachments:
9319 - FOI_5957 - Myelofibrosis and Oesophageal cancer.xlsx
 
To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.

Salisbury NHS Foundation Trust, Salisbury District Hospital, Salisbury, Wiltshire, SP2 8BJ
T: 01722 336262 E: sft.pals@nhs.net
© 2021 Salisbury NHS Foundation Trust
Trust Values